Backstepping Sliding Mode Gaussian Insulin Injection Control for Blood Glucose Regulation in Type I Diabetes Patient

2018 ◽  
Vol 140 (9) ◽  
Author(s):  
Akshaya Kumar Patra ◽  
Pravat Kumar Rout
Keyword(s):  
Blood Glucose ◽  
Sliding Mode ◽  
Type I Diabetes ◽  
State Space Model ◽  
Hybrid Approach ◽  
Insulin Injection ◽  
Diabetes Patient ◽  
Type I ◽  
Closed Loop Systems ◽  
Continuous Glucose Monitors

New efforts have been made to build up prototypes of subcutaneous closed-loop systems for controlling blood glucose (BG) levels in type I diabetes mellitus (TIDM) patients with the development of clinically accurate continuous glucose monitors, automated micro-insulin dispenser (MID), and control algorithms. There is an urgency to develop new control algorithm to determine the desired dose of insulin for maintaining normal BG levels. As a solution to the above issue, a novel backstepping sliding mode Gaussian controller (BSMGC) is proposed whose gains vary dynamically with respect to the error signal. A feedback control law is formulated by a hybrid approach based on BSMGC. A ninth-order linearized state-space model of a nonlinear TIDM patient with the MID is formulated for the design of the BSMGC. This controller is evaluated, and the results are compared with other recently published control techniques. The output responses clearly reveal the better performance of the proposed method to control the BG level within the range of normoglycaemia in terms of accuracy, robustness and handling uncertainties.

Sitagliptin (Januvia)

Top Drugs ◽  
2015 ◽  
Author(s):  
Jie Jack Li
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Type Ii Diabetes ◽  
Kidney Diseases ◽  
Type I Diabetes ◽  
Glycosylated Hemoglobin ◽  
Insulin Injection ◽  
Type I ◽  
Type Ii ◽  
Ancient Times

Diabetes has been known since antiquity. In fact, the term “diabetes mellitus” comes from the Greek meaning “siphon and honey” due to the excess excretion (siphon or faucet) of hyperglycemic (sweetened, or honeyed) urine associated with diabetes. In ancient times, diabetes was mostly type I, which usually manifests acutely in the young, secondary to certain underlying insults (possibly infections) to the islet cells of the pancreas resulting in an absolute lack of insulin. Insulin was discovered by Banting and Best in 1921, and insulin injection has literally saved millions of lives since then. With the wondrous efficacy that insulin bestows, type I diabetes is largely controlled because type I diabetes is insulindependent. However, type II diabetes, a more prevalent form of diabetes, is not insulin-dependent. In ancient times, when nutrition was scarce and obesity was not prevalent, type II diabetes mellitus (T2DM) was extremely rare. Indeed, type II diabetes is a disease more frequently associated with maturity, obesity, and gradually increasing blood glucose concentrations, and it may be asymptomatic for some time, only discovered on routine glucose screening. In fact, with the increasing body weight of the general population of the developed world, type II diabetes is becoming an epidemic. Serious complications of diabetes include nephropathy (kidney diseases), neuropathy (nerve damage), and retinopathy (blindness). Diabetes is the most common cause of blindness and amputation in the elderly in the United States. Oral diabetes drugs are required for most type II diabetic patients. Diabetes drugs may be classified into four categories: (a) agents that augment the supply of insulin such as sulfonylureas; (b) agents that enhance the effectiveness of insulin such as biguanides and thiazolidinediones; (c) GLP agonists; and (d) DPP4 Inhibitors. The efficacy of all the antidiabetic drugs can be monitored by measuring glycosylated hemoglobin (HaA1c) as a long term marker of elevated blood glucose. The amount of HaA1c reflects the average level over the last 120 days, the life span of a red blood cell, and should remain below 7%.

Co-Microencapsulation of BMSCs and Mouse Pancreatic (3 Cells for Improving the Efficacy of Type I Diabetes Therapy

2017 ◽  
Vol 40 (4) ◽  
pp. 169-175 ◽  
Author(s):  
Ruimin Long ◽  
Yuangang Liu ◽  
Shibin Wang ◽  
Li Ye ◽  
Peng He
Keyword(s):  
Stem Cells ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Type I Diabetes ◽  
Insulin Injection ◽  
Primary Study ◽  
Type I ◽  
Glucose Determination

Introduction To overcome the shortcomings of pancreas transplantation and insulin injection treatment for type I diabetes, biocompatible materials were used to prepare alginate-chitosan-alginate microcapsules that co-encapsulated bone marrow mesenchymal stem cells and mouse pancreatic β cells to treat diabetic mice. Methods Blank alginate-chitosan-alginate (ACA) microcapsules and co-microencapsulated cells were prepared using a high-voltage electrostatic method and then characterized using an inverted microscope. Cell viability was evaluated using AO/EB staining. ELISA kit was used to detect insulin secretion. Peri-orbital blood samples were obtained from the mice for blood glucose determination every week for one month. Results After 28 days of in vitro culture, the secretion of insulin following co-microencapsulation was higher than that observed for microencapsulated beta-TC-6 cells alone. On the 28th day after transplantation, the blood glucose level was 6.86 mmol/L in the microencapsulated beta-TC-6 group. On the 14th day, the blood glucose level was 6.80 mmol/L in the co-microencapsulated BMSC/beta-TC-6 group, which was close to the normal blood glucose level of healthy mice. These results indicated that the efficacy in reducing blood glucose was better in the co-microencapsulated BMSC/beta-TC-6 group. Conclusions This primary study indicated that combining microencapsulation technology and co-culture of stem cells and somatic cells shows promise for the treatment of type I diabetes mellitus.

Terminal Synergetic Control for Blood Glucose Regulation in Diabetes Patients

2018 ◽  
Vol 140 (10) ◽  
Author(s):  
A. Hachana ◽  
M. N. Harmas
Keyword(s):  
Blood Glucose ◽  
Sliding Mode ◽  
Type I Diabetes ◽  
System Stability ◽  
Diabetic Patients ◽  
Type I ◽  
Continuous Control ◽  
Control Scheme ◽  
Synergetic Control ◽  
Diabetes Patients

In this paper, a new robust terminal synergetic control scheme is proposed to regulate blood glucose level in diabetic patients (type I diabetes), based on recently developed synergetic control and a terminal attractor technique. The technique presented has the advantage of using a continuous control law. Moreover, the proposed control scheme, besides being chattering free, has the characteristics of finite time convergence. Lyapunov synthesis is adopted to ensure controlled system stability. Simulation results of terminal synergetic control are compared to classic synergetic and second-order sliding mode control (SMC) performance, demonstrating that the proposed control method allows for rapidly achieving normoglycemia in type I diabetes patients.

Predicting Blood Glucose Levels Around Meals for Patients With Type I Diabetes

2010 ◽  
Author(s):  
Fraser Cameron ◽  
Gu¨nter Niemeyer
Keyword(s):  
Blood Glucose ◽  
Type I Diabetes ◽  
Type I ◽  
Start Time ◽  
Predictive Algorithm ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Multiple Hypothesis ◽  
Continuous Glucose Monitors

Insulin pumps and continuous glucose monitors enable automatic control of blood glucose (BG) levels for patients with type 1 diabetes. Such controllers should carefully assess the likely future BG levels before injecting insulin, since the effects of insulin are prolonged, potentially deadly, and irreversible. Meals pose a strong challenge to this assessment as they create large, fast disturbances. Fortunately, meals have consistent and predictable effects, if their size and start time are known. We present a predictive algorithm that embeds meal detection and estimation into BG prediction. It uses a multiple hypothesis fault detector to identify meal occurrences, and linear Kalman filters to estimate meal sizes. It extrapolates and combines the state and state covariance estimates to form a prediction of BG values and uncertainties. These inputs enable controllers to assess and trade off the acute risks of low and chronic risks of high BG levels. We evaluate the predictor on simulated and clinical data.

Antidiabetic effect of Psychotria malayana Jack in induced type 1 diabetic rat

MEDISAINS ◽  
2020 ◽  
Vol 18 (1) ◽  
pp. 19
Author(s):  
Fairuz Fairuz ◽  
Hasna Dewi ◽  
Humaryanto Humaryanto
Keyword(s):  
Blood Glucose ◽  
Side Effects ◽  
Type I Diabetes ◽  
Langerhans Cell ◽  
Diabetic Rat ◽  
Type I ◽  
Antidiabetic Effect ◽  
Glucose Levels ◽  
Blood Glucose Levels

Background: Therapies for hyperglycemic treatment, including insulin and oral diabetes medications, have been confirmed to cause several side effects. Thus, finding new drugs with fewer side effects is of high importance. Salung leaf herb (Psychotria malayana Jack) reported used in traditional societies as a treatment for diabetes. However, the scientific proof of this plant for diabetes treatment is still lacking.Objective: To evaluate the antidiabetic effect of the P. malayana jack in induced type 1 diabetic rats by assessing blood glucose level and pancreatic cells in white rats.Methods: Alloxan used to induce type I diabetes. Rats randomly divided into six groups. A Group P1 received 250 mg/kg BW; group P2 received 500 mg/kg BW, group P3 received 1000 mg/kg BW. While group 4 basal received no treatment, group 5 received distilled water as a negative control, and group 6 received glibenclamide as a positive control. Medications are given for six days. Glucose levels were measured, and observation of pancreatic Langerhans cell damages.Results:  A decrease in blood glucose levels observed in all treatment groups. The most significant reduction (49.76%; 1000 mg/kg BW) occurred in the P3 group. Morphological features of pancreatic Langerhans cell damage were slightly high in the P1 group.Conclusion: P. malayana Jack can consider having an antidiabetic effect in a type 1 diabetic rat by reducing blood glucose levels.

Sign in / Sign up

Export Citation Format

Share Document